Herman and colleagues demonstrated a rapid and sustained downregulation of BCR and NF-κB signaling in CLL cells from both peripheral blood and tissue compartments during ibrutinib treatment, which was associated with decreased tumor proliferation. This evidence concerns the gene BCR and neoplasm.